intervention

Study/author/year

RVO type

N0. of patients

Duration

Vision outcome

Laser

photocoagulation

BVOS Group 1984 [24]

BRVO

Laser = 43

Control = 35

3 yrs.

Laser: 65% gained ≥ 2 line

Control: 37% gained ≥ 2 line

Ranibizumab

BRAVOCampochiaro et al., 2010 [43]

BRAVO Brown et al., 2011 [58]

BRVO

RBZ 0.5 mg = 131

RBZ 0.3 mg = 134

Control = 132

1 yr with primary endpoint at 6 mo

6-mo outcomes: RBZ 0.5 mg: +18.3 letters; 61.1% gained ≥3 lines, RBZ 0.3 mg: +16.6 letters; 55.2% gained ≥3 lines Sham: +7.3 letters; 28.8% gained ≥3 lines

Ranibizumab

CRUISE 2010 Brown et al., 2010 [44]

CRVO

RBZ 0.5 mg = 130

RBZ 0.3 mg = 132

Control = 130

6 mo

15-letter gain in ~17%, 46%, and 47% in sham, 0.3 mg, and 0.5 mg ranibizumab groups, respectively.

Bevacizumab

Epstein et al., 2012 [40] [41]

CRVO

IVB 2 mg = 30

Control = 30

6 mo

15-letter gain in 60% of bevacizumab vs. 20% of sham eyes

Aflibercept

VIBRANTCampochiaro et al., 2015 [46]

VIBRANT Clark et al., 2016 [47]

BRVO

IAI 2 mg = 91

Laser = 92

24-week

primary

endpoint, 1 yr study

24-wk results: IAI: +17.0 letters, 52.7% gained ≥3 lines, Laser: +6.9 letters, 26.7% gained ≥3 lines, 52-wkresults: IAI: +17.1 letters, 57.1% gained ≥3 lines, Laser/IAI: +12.2 letters, 41.1% gained ≥3 or more lines

Aflibercept

COPERNICUS Brown et al., 2013 [48]

CRVO

VTE 2 mg = 115

Control = 74

6 mo

15-letter gain in 56% of VTE eyes vs. 12% sham

Aflibercept

GALILEO Korobelnik et al., 2013 [49]

CRVO

VTE 2 mg = 106

Control = 71

52 weeks

15-letter gain in 60% of VTE eyes vs. 32.4% in sham

Pegaptanib sodium

Wroblewski et al., 2009 [51]

CRVO

Pegaptanib 0.3 mg = 33

Pegaptanib 1.0 mg = 33

Control = 32

30 weeks

36% and 39% of eyes treated with 0.3 mg and 1 mg pegaptanib gained ≥15 letters vs. 28% of sham

Triamcinolone Acetonide

SCORE Scott et al., 2009 [31]

BRVO

IVTA 4 mg = 138

IVTA 1 mg = 136

Laser = 137

12-mo primary endpoint 36 mo total

IVTA 4 mg: +4.0 letters, 27.2% gained ≥3 Lines, IVTA 1 mg: +5.7 letters; 25.6% gained ≥3 lines Laser: +4.2 letters, 28.9% gained ≥3 lines

SCORE Ip et al. 2009 [30]

CRVO

Total = 271, IVTA 4 mg, 1 mg vs Control

12 mo

15-letter gain in ~7%, 27%, and 26% for observation, 1 mg, and 4 mg groups, respectively

Dexamethasone

GENEVA Haller et al., 2010 [34] [35]

BRVO & CRVO

DEX 0.7 mg = 427,

DEX 0.35 mg = 414,

Control = 426,

6 mo

15-letter gain in 23%, 41%, and 40% for observation, 0.35 mg, and 0.7 mg DEX groups, respectively